Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Nilotinib

First Posted Date: 2011-01-11

Last Posted Date: 2020-09-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 112

Registration Number: NCT01274351

Locations: 🇹🇷
Novartis Investigative Site, Trabzon, Turkey

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Phase 1

Completed

Conditions: Advanced HER2-positive Breast Cancer

Interventions: Drug: AUY922
Drug: Trastuzumab

First Posted Date: 2011-01-07

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT01271920

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol

First Posted Date: 2011-01-07

Last Posted Date: 2016-11-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 625

Registration Number: NCT01272362

Locations: 🇫🇷
Novartis Investigative Site, Villefranche sur Saone, France

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Advanced Colorectal Cancer

Interventions: Drug: Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

First Posted Date: 2011-01-06

Last Posted Date: 2011-01-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01271166

Locations: 🇦🇺
Novarts Investigative Site, Melbourne, Australia

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms
Cancer
Tumors

Interventions: Drug: CHIR-258 (TKI258)

First Posted Date: 2011-01-05

Last Posted Date: 2011-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT01270906

Locations: 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

Phase 4

Withdrawn

Conditions: Kidney Transplantation

Interventions: Drug: Everolimus

First Posted Date: 2011-01-04

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01269684

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: QAX576
Drug: Placebo

First Posted Date: 2010-12-24

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT01266135

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Phase 4

Completed

Conditions: Renal Function and Chronic Allograft Vasculopathy

Interventions: Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Corticosteroids
Drug: Everolimus
Drug: Anti Thymocyte Globulin

First Posted Date: 2010-12-24

Last Posted Date: 2015-06-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 115

Registration Number: NCT01266148

Locations: 🇸🇪
Novartis Investigative Site, Lund, Sweden

Cardiac Safety of Indacaterol

Phase 1

Completed

Conditions: Healthy Volunteers
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 150 µg
Drug: Indacaterol 300 µg
Drug: Indacaterol 600 µg
Drug: Placebo
Drug: Placebo/moxifloxacin

First Posted Date: 2010-12-21

Last Posted Date: 2010-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 404

Registration Number: NCT01263808

Locations: 🇺🇸
Novartis investigative site, Miami, Florida, United States

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Phase 1

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Drug: Everolimus followed by Pasireotide LAR + Everolimus

First Posted Date: 2010-12-20

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01263353

Locations: 🇩🇪
Novartis Investigative Site, Muenster, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy